An eye-opening overall response rate of 32.7 percent in Phase II trials with antibody-drug conjugate TDM-1 in last-resort breast cancer patients left investors in ImmunoGen Inc. with well-founded hope that partner Roche Holdings AG will file for approval in the first half of next year and get an accelerated nod from the FDA. (BioWorld Today) Read More
